Prevention of Decompensation in Liver Cirrhosis

• Status: Unknown status
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Odense University Hospital
• Collaborators: Else Poulsen Mindelegat; Lundbeck Foundation; University of Southern Denmark
• Treatments: Losartan

Criteria

Inclusion Criteria:

The presence of cirrhosis in a liver biopsy; or, in the absence of histology, clinical and laboratory evidence of cirrhosis combined with years of excessive alcohol intake.

Age 18-70 years

Exclusion Criteria:

1. Cirrhosis due to alpha1-antitrypsin deficiency, viral hepatitis or autoimmunity.

2. Renal disease evidenced by proteinuria > 0,5 g/day.

3. Heart disease

4. Hypertension

5. Cancer or disease other than cirrhosis expected to limit life expectancy to < 5 years.

6. Pregnancy or lactation

7. Sepsis within 5 days

8. Gastrointestinal bleeding within 5 days